Outlook Therapeutics Seeks Resolution in FDA Dispute Over Eye Drug

Outlook Therapeutics initiates formal FDA dispute to overturn CRL for its wet AMD drug LYTENAVA, with a pivotal meeting set for April 2026.

Outlook Therapeutics has initiated a formal dispute resolution process with the U.S. Food and Drug Administration, marking a pivotal strategic move following a regulatory setback. The biopharmaceutical company is contesting the FDA's decision to issue a Complete Response Letter (CRL) for its investigational therapy, ONS-5010 (LYTENAVA™), intended to treat wet age-related macular degeneration (AMD). This procedural step represents a critical effort to gain market access in the United States.

The regulatory body issued the CRL in late December 2025, declining initial approval for the ophthalmic formulation. In a recent development on April 7, 2026, Outlook Therapeutics confirmed the FDA's official acceptance of its request for a Formal Dispute Resolution Request (FDRR). The company's strategy hinges on clinical data from its NORSE TWO Phase 3 trial, supplemented by findings from the NORSE EIGHT study. A significant point in its appeal is the absence of any safety concerns raised by the agency during its prior review of the drug candidate.

Key Meeting Scheduled for April 2026

A preparatory discussion was held on March 2 to clarify positions ahead of a decisive meeting scheduled for April 2026. This upcoming engagement is expected to define the specific requirements Outlook Therapeutics must meet to rectify the status of its application. The outcome will determine whether the company can access the lucrative U.S. market without undertaking lengthy new clinical trials or if additional regulatory obstacles will cause significant delays.

While the U.S. process faces challenges, the drug has already secured marketing authorization in the European Union and the United Kingdom. Commercial launch has commenced in initial European markets, providing a contrast to the ongoing regulatory discussions stateside. Outlook Therapeutics aims to position LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab.

Market Volatility Reflects Investor Uncertainty

The announcement of the formal dispute process triggered notable volatility in the company's share price. Investors reacted with pronounced swings on Tuesday, reflecting the high stakes of the procedure. The near-term future of Outlook Therapeutics in the U.S. is contingent on the resolution of these talks, leaving uncertainty over the regulatory pathway until a conclusion is reached. The financial markets are clearly mirroring the nervousness surrounding the April meeting's potential outcomes.